China now devotes more to research than the United States. In purchasing power parity, both countries have each crossed the 1 trillion dollar threshold in R&D spending, but it is Beijing that has taken the lead according to the latest OECD data published in March 2026. That same year, the Nature Index — which catalogs publications in top-tier scientific journals — credited China with 37,273 articles compared to 31,900 for the United States. This is no longer a trend: it is a documented turning point.

What makes this moment singular is not that China is progressing. It is that the United States is retreating of its own volition. While Beijing intensifies its investment in science over the course of two decades, Washington discusses federal cuts potentially reaching 20% of research funding. Economic estimates associated with such a withdrawal approach 1 trillion dollars in GDP lost over ten years. What is at stake is not a ranking. It is an ecosystem built over eighty years.

The Essentials

  • China surpasses the United States in R&D spending in purchasing power parity according to the OECD (March 2026), with 37,273 articles in the Nature Index compared to 31,900 on the American side
  • This surpassing is the fruit of two decades of sustained Chinese public investment, embodied by plans like “Made in China 2025” and national programs of mega-universities
  • In the United States, federal cuts of 20% to the research budget could reduce GDP by approximately 1 trillion dollars over ten years according to economic modeling
  • The American ecosystem rests on elements that are difficult to reconstitute: universities open to foreign researchers, national laboratories, financing indifferent to short-term profit

Thirty Years of Deliberate Escalation

In 1995, China devoted less than 0.6% of its GDP to research and development. It now stands at more than 2.6%, according to OECD data, and the trajectory remains oriented upward. This raw figure does not tell the whole story: we must add to it the demographic mass of trained researchers, investments in university infrastructure, and the priority accorded to strategic disciplines — artificial intelligence, semiconductors, biotechnologies, clean energy.

The “Made in China 2025” plan, launched in 2015, crystallized this ambition in the eyes of the external world. But the dynamic preceded it. Since the 1990s, each five-year plan has increased the share of public spending devoted to science. Chinese universities recruited massively from the best Western institutions, sometimes by offering comparable salary conditions, often by appealing to a return to roots for foreign-trained researchers of Chinese origin. The result is measurable: the number of researchers in China has more than doubled in twenty years.

What the Nature Index captures is quality as much as volume. The 37,273 Chinese articles recorded do not come solely from second-tier publications. Institutions like Peking University, Tsinghua, the Chinese Academy of Sciences now figure among the most productive in the world in domains as competitive as materials physics, chemistry, or life sciences. The gap with the United States is not yet uniform across disciplines, and the United States retains a qualitative advantage in certain cutting-edge sectors — but the axis of the trend is unambiguous.

What the 1 Trillion Dollar Figure Hides

Comparing R&D spending in purchasing power parity is the most honest method for measuring real effort. It corrects distortions linked to differences in wage costs and infrastructure. But it does not tell the whole story either.

In the United States, R&D remains overwhelmingly concentrated in the private sector: large technology companies — Apple, Google, Microsoft, Nvidia — represent a considerable fraction of the national total. This private financing is oriented toward commercial applications on a relatively short horizon. Fundamental research, the kind that produces unforeseen breakthroughs over twenty or thirty years, is financed primarily by federal institutions: the National Science Foundation, the National Institutes of Health, the Department of Energy, DARPA. These are precisely the budget lines targeted by the cuts discussed since 2025.

In China, the structure is inverted. The State remains the primary funder and director of research, with the advantages and limitations that this entails. The advantage: a capacity to concentrate massive resources on defined national priorities, without short-term market arbitration. The limitation: fundamental research still partially constrained by political logics, and a culture of scientific risk-taking that differs from that of American or European laboratories where failure is more accepted as a normal step.

The comparison of the 1 trillion dollars on each side thus conceals two distinct models. What worries economists and historians of science is less that China exceeds this figure than that the United States begins to move away from it downward.

The American Ecosystem, Capital Difficult to Reconstitute

The American scientific advantage of the twentieth century did not rest on a single lever. It depended on a combination of mutually reinforcing elements: world-class universities open to international talent, patient federal financing oriented toward fundamental science, national laboratories capable of very long-term projects like supercolliders or the sequencing of the human genome, and an entrepreneurial culture of risk that transformed academic discoveries into companies.

This combination was not built in a five-year plan. It is the fruit of investments following the Second World War, of the Sputnik shock of 1957, of the Cold War that made scientific research a national security priority. The laboratories of Midwest public universities, the California campuses of the UC System, the research centers of the NIH in Bethesda: these are institutions that had decades to build their reputation, their networks, their capacity to attract the best researchers from around the world.

A federal withdrawal of 20% would not merely cut budget lines. It would send a signal to this international community of researchers for whom the United States represented the default address. A signal that the Trump administration has already begun to emit through other channels: visa restrictions, tensions around researchers of foreign origin, nationalist rhetoric directed at academic institutions. Recent data show a decline in foreign applications to several top American universities for the 2025-2026 academic year.

Economist Tyler Cowen, who had documented the American slowdown in innovation in the 2010s, noted recently that AI seemed to revive American productivity. This reading, based on the vitality of the private technology sector, is consistent with short-term data. It does not answer the question of what will fuel the next wave of innovation if fundamental research degrades over twenty years.

The 1 Trillion Dollars Lost: An Estimate to Be Read with Caution

The figure of 1 trillion dollars in GDP lost over ten years in the event of a 20% cut to federal research funding has circulated in American economic policy debates since 2025. It stems from econometric modeling that rests on historical work linking public R&D investment and long-term growth.

These estimates deserve to be read with the caution demanded by all ten-year projections. The economic multipliers of research are well documented in academic literature — a dollar invested in federal R&D typically generates multiple dollars of economic return over the long term, according to studies covering National Science Foundation and NIH spending over the past fifty years. But the precision of a figure like 1 trillion dollars depends on assumptions about complex causal chains: how private companies do or do not compensate for public cuts, how researchers relocate their activities, how unrealized fundamental discoveries propagate in the absence of commercial applications.

What is well established, on the other hand, is the direction. The United States built its technological advantage on a combination of public and private research. Cutting the first element is to weaken the second in the long term. The major American technology companies that dominate the sector of artificial intelligence today are largely heirs to federal investments from the 1970s to 2000 in networks, computing, and applied mathematics. The internet was funded by DARPA. Machine learning algorithms came from university laboratories largely subsidized by public funds.

What Europe Can Learn From This

For Europeans observing this turning point, the temptation is twofold: to see in China’s growing power a threat, and to see in American retreat an opportunity to seize. Both readings have their share of truth, but neither fully expresses what is essential.

Europe has no vocation to copy the Chinese model of state concentration of research. It lacks the institutional structure for it moreover — European R&D remains fragmented among member states, national universities, and a few common programs like Horizon Europe, endowed with 95 billion euros for the 2021-2027 period. This budget, significant in absolute value, remains modest when measured against the total effort of the United States or China.

What this turning point reveals is the fragility of scientific advantages when public investment weakens. Europe has its own examples of chronic underinvestment in fundamental research — France spends approximately 2.2% of its GDP on R&D, far from the 3% objective of the Lisbon agenda formulated in 2000 and never reached. Germany approaches this with 3.1%. The European Union as a whole hovers around 2.2%.

The true lesson is not geopolitical. It is institutional: a country that ceases to finance its science does not see the consequences in the quarters that follow. It sees them twenty years later, when the laboratories it should have built do not exist, when the researchers it should have trained work elsewhere, when the technologies it should have mastered are sold to it by others.

The Fundamental Research Market Does Not Self-Regulate

There is an argument regularly advanced to minimize concerns: the American private sector will continue to invest massively, notably in AI, biotechnologies, and energy. Apple, Microsoft, Alphabet, and their equivalents in pharmaceuticals or energy collectively spend hundreds of billions in R&D each year. Why would federal retreat be problematic if the private sector fills the void?

The answer lies in the nature of fundamental research. A pharmaceutical laboratory seeks molecules that can become medications sold within ten years. It does not finance the understanding of cellular mechanisms that will have no commercial application until 2060. A digital giant invests in AI models that improve its current products. It does not finance the theoretical mathematics on which perhaps the next computational breakthrough will depend. Fundamental research has a characteristic that the market handles poorly: its benefits are diffuse, late in coming, and non-appropriable. It is precisely for this reason that it is financed by public power in every country that has succeeded in building a durable scientific advantage.

This logic applies to Europe as much as to the United States. It also explains why China, despite its measurable successes in publications and spending, continues to finance its fundamental research massively through the State rather than relying on the market. Beijing has understood something that Washington seems to be forgetting.

The question that now arises is less whether China will maintain its trajectory — nothing structurally prevents it in the short term — than whether American research institutions will find the political resources to resist cuts or the institutional repercussions to compensate for them. Some universities have already begun to diversify their funding toward private foundations and international partnerships. But these substitutes do not replace patient federal financing oriented toward long-term scientific risk. The precarization of knowledge workers, which Paul Osterman documented for the entire American labor market, now touches the scientific community itself.

Sources

  1. UPI / Analysis — China surpasses United States in research spending (April 2026)
  2. OECD — Main Science and Technology Indicators, March 2026
  3. Nature Index — ranking data 2025-2026 by institution and country
  4. National Science Foundation — report on federal R&D spending (historical series)